BioWisdom CSO to Speak at DIA Conference
Julie Barnes PhD, CSO of BioWisdom Ltd, the market leader in delivering healthcare intelligence to the pharmaceutical industry, today presented at the Drug Information Association (DIA) conference in Madrid. The DIA conference is considering Pharmacovigilance (PV) and Clinical Data Management (CDM) and ways of managing safety data more effectively, with a specific focus on embracing new technologies for improving the processing and interpretation of adverse events. Dr Barnes is presenting on the current issues associated with the interpretation of safety data originating from preclinical safety assessments, clinical trials or post marketing pharmacovigilance studies. She looks specifically at Intelligence Networks, which provide a contextual and meaningful layer onto data and information generated during the preclinical, clinical and post-marketing phases of R&D. Intelligence Networks can be used to identify risk factors for adverse events, aid the design of clinical trials and assist in the interpretation of safety signals seen in clinical trials and pharmacovigilance studies. Dr Julie Barnes, CSO of BioWisdom, said: "There is an urgent need for a greater understanding of the mechanisms underpinning serious adverse events associated with pharmaceutical products. At BioWisdom, our market-leading technology, Sofia, SRS and Omniviz, is being used extensively in this area to support decision making across the industry and is providing insight into mechanisms of drug liability."
ABOUT BIOWISDOM
BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development.
For further information please visit www.biowisdom.com
ABOUT DIA, Madrid
The Drug Information Association (DIA) is a professional association of more than 18,000 members worldwide who are involved in the discovery, development, regulation, surveillance, or marketing of pharmaceuticals or related products. DIA is committed to the broad dissemination of information among its members, with continuously improved professional practice as the goal. DIA serves its members in a neutral, global environment that operates independent of the influence of any one organization or authority. DIA operates as a financially independent non-profit organization that funds itself from meeting and membership fees. The voluntary efforts of DIA members and speakers allow DIA to provide programs and publications to members at a reasonable, competitive cost.
The DIA Clinical Forum 2007 features 11 conferences, workshops and training courses covering the areas of Clinical Data Management, eClinical, Clinical R&D, Project Management for Clinical Trials, Pharmacovigilance, Statistics, Knowledge Management, Medical Writing, Medical Information and Communications, Information Technology and Innovative Medicines.
